Clinical Trials · NCT01315795
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 59
- Start date
- Mar 2011
- Locations
- 1 site, Belgium
- Primary endpoint
- Reduction of total liver volume after 6 months of treatment measured by means of CT-scan.